Episode 389: ASCO GU 2025 - NIAGARA Pathologic CR Updates and Outcomes

By The Uromigos - Last Updated: February 14, 2025

Dr. Matt Galsky joins the show to discuss pathological complete response rates from the NIAGARA trial and its clinical implications.

Post Tags:Uromigos-Bladder Cancer

Advertisement

Related Podcasts

Episode 392: ASCO GU 2025 - HIF Inhibition With Casdatifan in Refractory RCC

Uromigos-Kidney Cancer

Episode 391: ASCO GU 2025 - KIM-1 Data From CheckMate 214

Uromigos-Kidney Cancer

Episode 390: ASCO GU 2025 - Pembro-Based Doublets in Refractory RCC and COSMIC-313 OS Update

Uromigos-Kidney Cancer

Episode 388: ASCO GU 2025 - FGFR3 Inhibition With LOXO-435 in Urothelial Cancer

Uromigos-Bladder Cancer

Episode 387: ASCO GU 2025 - Neoadjuvant Disitamab Vedotin + Toripalimab in HER2+ MIBC: Updated Efficacy and Safety Results

Uromigos-Bladder Cancer

Advertisement

Advertisement